Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis
(Source: Patient Preference and Adherence)
Source: Patient Preference and Adherence - April 10, 2024 Category: International Medicine & Public Health Tags: Patient Preference and Adherence Source Type: research
Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States
CONCLUSIONS: In this real-world study, similar treatment persistence, dose escalation, and rates of opportunistic or serious infections were observed with VDZ- and UST-treated patients with CD. However, VDZ was associated with a significantly lower cost outlay for healthcare systems.PMID:38586979 | DOI:10.1080/03007995.2024.2326585 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - April 8, 2024 Category: Research Authors: Michael Chiorean Jeanne Jiang Ninfa Candela Grace Chen Hela Romdhani Dominick Latremouille-Viau Sherry Shi Rebecca Bungay Annie Guerin Tao Fan Source Type: research
Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review
ConclusionAvailable information suggests that the anatomical and physiological changes throughout pregnancy may have meaningful effects on the PK of mAbs. For most mAbs (not IFX), modestly higher dosing (per mg) maybe needed during pregnancy to sustain a similar serum exposure compared to pre-pregnancy. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - April 7, 2024 Category: Drugs & Pharmacology Source Type: research
Simulated cost ‐effectiveness of a novel precision‐guided dosing strategy in adult patients with Crohn's disease initiating infliximab maintenance therapy
ConclusionsPGD provides clinical and QoL benefits by maintaining remission and avoiding IFX failure; it is the most cost-effective under conservative assumptions. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 5, 2024 Category: Drugs & Pharmacology Authors: Elmar R. Alizadeh,
Thierry Dervieux,
Severine Vermeire,
Marla Dubinsky,
Geert D'Haens,
David Laharie,
Andrew Shim,
Byron P. Vaughn Tags: RESEARCH ARTICLE Source Type: research
Correction
Colombel J-F, Sands, BE, Gasink C, et al. Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn’s Disease. Clin Gastroenterol Hepatol 2024; 22:144-153.e2 (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - April 3, 2024 Category: Gastroenterology Tags: Correction Source Type: research
Short-term effectiveness and potential factors of ustekinumab based on real-world data in Chinese psoriasis patients
CONCLUSION: In this study, nearly one-third of patients achieved PASI 75 after only the first-dose ustekinumab treatment. Sex, family history of psoriasis, MS, serum TG level might affect the short-term effectiveness, and serum HDL-C level may be a potential factor. The possibility of achieving treatment goals (PASI 75/90/100) at week 4 increased along with serum HDL-C levels.PMID:38531383 | DOI:10.1080/09546634.2024.2321188 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - March 26, 2024 Category: Dermatology Authors: Xingyu Li Xiaowen Xie Jiashuai Li Jingjin Hu Kun Hu Minjia Tan Jing Yang Sichun Deng Yijie Liu Mi Zhang Yehong Kuang Junchen Chen Liqiu Liao Wu Zhu Source Type: research
Ustekinumab-induced leukocytoclastic vasculitis in a young male with Crohn's disease
Ustekinumab-induced Leukocytoclastic Vasculitis in a Young Male with Crohn's disease (Source: Digestive and Liver Disease)
Source: Digestive and Liver Disease - March 24, 2024 Category: Gastroenterology Authors: Xiao-Peng Zhang, Huan Wang, Liang-ru Zhu Tags: Image of the Month Source Type: research
Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies
ConclusionAcross both clinical studies and real-world settings, more patients treated with IXE achieved NPF target and acceptable responses at week 12 compared with those treated with other biologics.Trial RegistrationUNCOVER-2 (NCT01597245); UNCOVER-3 (NCT01646177); IXORA-R (NCT03573323); IXORA-S (NCT02561806); PSoHO (EUPAS24207). (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - March 23, 2024 Category: Dermatology Source Type: research
